Kyung Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 16, 2022 at 12:17 pm IST
Share
Kyung Dong Pharmaceutical Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was KRW 40,294.2 million compared to KRW 42,403.96 million a year ago. Net loss was KRW 1,206.07 million compared to net income of KRW 1,905.69 million a year ago. Basic loss per share from continuing operations was KRW 44 compared to basic earnings per share from continuing operations of KRW 69 a year ago. Basic loss per share was KRW 44 compared to basic earnings per share of KRW 69 a year ago.
For the six months, sales was KRW 6,635.45 million compared to KRW 6,660.4 million a year ago. Net income was KRW 2,041.2 million compared to KRW 5,533.91 million a year ago. Basic earnings per share from continuing operations was KRW 75 compared to KRW 200 a year ago. Basic earnings per share was KRW 75 compared to KRW 200 a year ago.
KYUNG DONG PHARMACEUTICAL CO.,LTD. is a Korea-based company engaged in the manufacture and marketing of pharmaceutical products. The Companyâs products include liver therapies, gastrointestinal drugs, antimigraine drugs, antiviral, anti-obesity medications, antibacterial drugs, antidiabetic drugs, antifungal, allergy medications, antispasmodics, antihistamines, vitamins, as well as drugs for osteoporosis, cardiovascular, muscle relaxant, neuropathic and other diseases. It also provides various over-the-counter (OTC) drugs, such as anti-inflammatory medicines, antiviral drugs, antihistamine drugs, gastrointestinal drugs and others. In addition, the Company engages in the leasing of real estate, and distribution of snowboards and health functional food.
KYUNG DONG PHARMACEUTICAL CO., LTD. 
